{"id":"agn-241751","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased risk of atrial fibrillation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking Nav1.5, AGN-241751 aims to reduce the abnormal electrical activity in the heart that can lead to atrial fibrillation. This mechanism is thought to be beneficial for patients with atrial fibrillation who are at risk of stroke.","oneSentence":"AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:22.489Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT04981561","phase":"PHASE1","title":"Safety and Tolerability of Zelquistinel in Normal Human Volunteers","status":"COMPLETED","sponsor":"Syndeio Biosciences, Inc","startDate":"2016-12-09","conditions":"Major Depressive Disorder","enrollment":68},{"nctId":"NCT03726658","phase":"PHASE1, PHASE2","title":"AGN-241751 in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Syndeio Biosciences, Inc","startDate":"2018-11-08","conditions":"Major Depressive Disorder","enrollment":226},{"nctId":"NCT03586427","phase":"PHASE2","title":"AGN-241751 in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Syndeio Biosciences, Inc","startDate":"2018-06-13","conditions":"Depressive Disorder, Major","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-241751","genericName":"AGN-241751","companyName":"Syndeio Biosciences, Inc","companyId":"syndeio-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}